A&G Pharmaceutical, Inc. and Celltrion, Inc. have entered into an agreement for clinical production of a novel A&G theranostic monoclonal antibody. Celltrion will perform bioprocess development, scale-up, and cGMP manufacturing and provide all clinical materials to support toxicology studies as well as Phase I and Phase II U.S. clinical studies on A&G's anti-GP88 monoclonal antibody.
PR Newswire